5:42 PM
 | 
Nov 19, 2012
 |  BC Extra  |  Clinical News

Additional Phase III data for Avastin in glioblastoma

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit reported additional data showing that Avastin bevacizumab plus temozolomide and radiation led to a median progression-free survival (PFS), a co-primary endpoint, of 10.6 months vs. 6.2 months for placebo plus temozolomide and radiation (HR=0.64, p<0.0001) in the Phase III AVAglio trial...

Read the full 236 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >